Table 2. . Comparison of provider utilization (number of pharmacogenetic tests ordered/number of eligible prescriptions) in the pharmacist-in-house arm and the pharmacist-on-call arm.
| Drug/gene (PGx test) |
# of PGx tests ordered/# of new prescriptions |
|||||
|---|---|---|---|---|---|---|
|
Preintervention |
Intervention |
Postintervention |
||||
| Pharmacist in-house | Pharmacist on-call | Pharmacist in-house | Pharmacist on-call | Pharmacist in-house | Pharmacist on-call | |
| Atomoxetine† (CYP2D6) |
0/0 |
0/0 |
0/0 |
0/3 |
0/1 |
0/1 |
| Carbamazepine (CYP2C9) |
0/0 |
0/0 |
0/0 |
0/2 |
0/0 |
0/0 |
| Celecoxib† (CYP2C9) |
0/2 |
0/10 |
2/2 |
0/8 |
0/3 |
0/5 |
| Clopidogrel (CYP2C19) |
0/2 |
0/6 |
1/1 |
0/1 |
0/1 |
0/3 |
| Codeine (CYP2D6) |
0/19 |
0/41 |
1/43 |
0/50 |
0/18 |
0/17 |
| Esomeprazole† (CYP2C19) |
0/8 |
0/10 |
0/2 |
0/15 |
0/4 |
0/6 |
| Fluoxetine† (CYP2D6) |
0/7 |
0/8 |
5/11 |
0/20 |
0/4 |
0/10 |
| Imipramine (CYP2D6) |
0/0 |
0/1 |
0/0 |
0/0 |
0/0 |
0/0 |
| Metoprolol† (CYP2D6) |
0/20 |
0/21 |
5/20 |
0/35 |
0/4 |
0/12 |
| Nortriptyline (CYP2D6) |
0/3 |
0/3 |
0/0 |
0/3 |
0/1 |
0/0 |
| Simvastatin‡ (SLCO1B1) |
0/18 |
0/25 |
33/20§ |
12/16 |
0/6 |
0/7 |
| Warfarin (VKORC1/CYP2C9) |
0/9 |
0/4 |
1/1 |
3/5 |
0/0 |
0/0 |
| Total | 0/88 | 0/129 | 48/100 | 15/158 | 0/42 | 0/61 |
†Clinical Pharmacogenetics Implementation Consortium or other guidelines not available for this drug.
‡Not mentioned in US FDA approved package insert.
§ SLCO1B1 testing was ordered for 33 patients, six of whom were already taking simvastatin for at least 1 month, nine for whom statin treatment was indicated but not yet prescribed during the intervention period and 18 who were prescribed simvastatin at the time testing was ordered or after test results were available.
PGx: Pharmacogenetic.